

Muhammad Umair Mushtaq

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1495854/publications.pdf>

Version: 2024-02-01

89
papers

904
citations

567144

15
h-index

526166

27
g-index

92
all docs

92
docs citations

92
times ranked

1161
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
2	Dietary behaviors, physical activity and sedentary lifestyle associated with overweight and obesity, and their socio-demographic correlates, among Pakistani primary school children. International Journal of Behavioral Nutrition and Physical Activity, 2011, 8, 130.	2.0	92
3	Prevalence and socio-demographic correlates of stunting and thinness among Pakistani primary school children. BMC Public Health, 2011, 11, 790.	1.2	81
4	Waist circumference, waist-hip ratio and waist-height ratio percentiles and central obesity among Pakistani children aged five to twelve years. BMC Pediatrics, 2011, 11, 105.	0.7	76
5	Urban-rural inequities in knowledge, attitudes and practices regarding tuberculosis in two districts of Pakistan's Punjab province. International Journal for Equity in Health, 2011, 10, 8.	1.5	66
6	Height, weight and BMI percentiles and nutritional status relative to the international growth references among Pakistani school-aged children. BMC Pediatrics, 2012, 12, 31.	0.7	66
7	Prevalence and socioeconomic correlates of overweight and obesity among Pakistani primary school children. BMC Public Health, 2011, 11, 724.	1.2	47
8	Public health in British India: A brief account of the history of medical services and disease prevention in colonial India. Indian Journal of Community Medicine, 2009, 34, 6.	0.2	47
9	Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Transplantation and Cellular Therapy, 2021, 27, 796.e1-796.e7.	0.6	42
10	Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplantation and Cellular Therapy, 2022, 28, 358-364.	0.6	40
11	Family-based factors associated with overweight and obesity among Pakistani primary school children. BMC Pediatrics, 2011, 11, 114.	0.7	28
12	Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transplant Infectious Disease, 2022, 24, .	0.7	28
13	Are we doing enough? Evaluation of the Polio Eradication Initiative in a district of Pakistan's Punjab province: a LQAS study. BMC Public Health, 2010, 10, 60.	1.2	27
14	Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 877.e1-877.e8.	0.6	20
15	From their own perspective - constraints in the Polio Eradication Initiative: perceptions of health workers and managers in a district of Pakistan's Punjab province. BMC International Health and Human Rights, 2010, 10, 22.	2.5	19
16	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leukemia and Lymphoma, 2019, 60, 2558-2562.	0.6	13
17	Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 158-166.	0.6	10
18	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open, 2021, 6, 100172.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Prognostic Significance of Bone Marrow Involvement in Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 5370-5370.	0.6	6
20	Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. <i>Transplant Immunology</i> , 2022, 70, 101520.	0.6	6
21	Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1708-1713.	0.6	6
22	Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5246-5246.	0.6	5
23	Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	4
24	Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18562-e18562.	0.8	3
25	Socio-demographic correlates of the health-seeking behaviours in two districts of Pakistan's Punjab province. <i>JPMA the Journal of the Pakistan Medical Association</i> , 2011, 61, 1205-9.	0.1	3
26	Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis. <i>Blood</i> , 2019, 134, 1270-1270.	0.6	2
27	Telehealth to increase access to transplant survivorship care for allogeneic stem cell transplant recipients regardless of distance to transplant center or neighborhood income.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13615-e13615.	0.8	2
28	Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19014-e19014.	0.8	2
29	Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7062-7062.	0.8	2
30	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	2.3	2
31	Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18611-e18611.	0.8	1
32	Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19021-e19021.	0.8	1
33	Pre-therapy neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio do not predict survival in patients treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15092-e15092.	0.8	1
34	Single Institution Experience with Myeloma Patients for Commercially Approved BCMA Chimeric Antigen Receptor T Cell Therapy (CART) Idecabtagene-Vicleucel (Ide-cel). <i>Transplantation and Cellular Therapy</i> , 2022, 28, S233-S234.	0.6	1
35	Immunogenicity of Sars-Cov-2 Vaccination in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S46-S47.	0.6	1
36	Aleukaemic leukaemia cutis. <i>British Journal of Haematology</i> , 2015, 170, 4-4.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Retrospective Analysis of Factors Associated With Venous Thromboembolism Among Pancreatic Cancer Patients. <i>Pancreas</i> , 2018, 47, e52-e53.	0.5	0
38	Role of biogenetic markers in differentiation and prognosis of giant cell tumor: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23514-e23514.	0.8	0
39	Healthcare access disparity among U.S. cancer population and evaluation of social determinants of health using NHANES data for 2013-18.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18527-e18527.	0.8	0
40	A systematic review of post-transplant lymphoproliferative disorder after renal transplantation.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19577-e19577.	0.8	0
41	A systematic review of post-transplant lymphoproliferative disorder after liver transplant.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19045-e19045.	0.8	0
42	Various treatment options for the management of Campanacci III giant cell bone tumor.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23509-e23509.	0.8	0
43	The impact of atrial fibrillation on hospitalization outcomes for patients with chronic lymphocytic leukemia: A large database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19508-e19508.	0.8	0
44	Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19025-e19025.	0.8	0
45	Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7033-7033.	0.8	0
46	Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19035-e19035.	0.8	0
47	Role of adjunct plasma exchange or high cut-off hemodialysis in the management of myeloma cast nephropathy: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20032-e20032.	0.8	0
48	Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11020-11020.	0.8	0
49	Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20014-e20014.	0.8	0
50	Management of light chain deposition disease: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20042-e20042.	0.8	0
51	A systematic review of post-transplant lymphoproliferative disorder after lung transplant.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19046-e19046.	0.8	0
52	Association of Pre-chemotherapy neutrophil-to-lymphocyte ratio with overall survival in underserved pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15241-e15241.	0.8	0
53	Association of neutrophil-to-lymphocyte ratio with overall survival in underserved patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15263-e15263.	0.8	0
54	Factors associated with venous thromboembolism among pancreatic cancerpatients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15285-e15285.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Lab Indicators of Iron Level in Bone Marrow Aspirate of Patients Diagnosed with Multiple Myeloma. Blood, 2015, 126, 5397-5397.	0.6	0
56	Comparison of International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) in myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2016, 34, e18549-e18549.	0.8	0
57	Prognostic significance of bone marrow cellularity in myelodysplastic syndromes: a retrospective analysis.. Journal of Clinical Oncology, 2016, 34, e18550-e18550.	0.8	0
58	Prognostic score to predict time to castration-resistance in underserved patients with metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16518-e16518.	0.8	0
59	Factors Associated with Bleeding Events in Patients Receiving Rivaroxaban for Venous Thromboembolism: A Real World Experience. Blood, 2018, 132, 5064-5064.	0.6	0
60	Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 2708-2708.	0.6	0
61	Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). Blood, 2019, 134, 3088-3088.	0.6	0
62	Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3147-3147.	0.6	0
63	Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4389-4389.	0.6	0
64	Evolution in Resource Utilization for Unique Toxicities Related to Chimeric Antigen Receptor T Cell Therapy from 2017 to 2020: A Database Review. Blood, 2021, 138, 4844-4844.	0.6	0
65	Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3961-3961.	0.6	0
66	Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4825-4825.	0.6	0
67	Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4683-4683.	0.6	0
68	Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3963-3963.	0.6	0
69	Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting. Blood, 2021, 138, 2823-2823.	0.6	0
70	Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis. Blood, 2021, 138, 4410-4410.	0.6	0
71	Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1848-1848.	0.6	0
72	Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4910-4910.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Outcomes with Interferon in Polycythemia Vera: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3659-3659.	0.6	0
74	Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1847-1847.	0.6	0
75	Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2863-2863.	0.6	0
76	Impact of Natural Killer Cells Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4880-4880.	0.6	0
77	Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. Blood, 2021, 138, 4790-4790.	0.6	0
78	Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4831-4831.	0.6	0
79	Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4824-4824.	0.6	0
80	Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. Transplantation and Cellular Therapy, 2022, 28, S453-S454.	0.6	0
81	Outcomes of Autologous Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S412-S413.	0.6	0
82	Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S119.	0.6	0
83	Socioeconomic and Racial Barriers to CD19 Chimeric Antigen Receptor T Cell Therapy (CART) Access. Transplantation and Cellular Therapy, 2022, 28, S208.	0.6	0
84	Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S122.	0.6	0
85	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S416-S417.	0.6	0
86	Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S204.	0.6	0
87	Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation: A Systemic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S262-S263.	0.6	0
88	Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leukemia and Lymphoma, 2022, 63, 2671-2678.	0.6	0
89	Role of metformin in the treatment of cholangiocarcinoma: A systematic review.. Journal of Clinical Oncology, 2022, 40, e16132-e16132.	0.8	0